"These companies have taken a risk to transfer technology and scale up these vaccines at their cost. SII took the technology from Oxford University who wanted a partner. We are prepared to give them clinical supplies," says Kiran Mazumdar Shaw, Executive Chairperson, Biocon, to NDTV.
